Mount Sinai Liver Cancer Program: 16th Anniversary Liver Cancer: Advances in Science and Clinical Management

Friday, December 17, 2021, 8:30 AM - 5:00 PM, Virtual


Targeted physicians are not aware of the impact of new therapies in HCC and cholangiocarcinoma in the clinical practice. There is a need to educate clinicians on the cutting-edge research in liver cancer, particularly regarding new insights in the pathogenesis of the disease and new molecular and immune therapies. Finally, new discoveries in the principles of management of COVID-19 in patients with liver cancer will help physicians to improve their decision-making process. The program is aimed to both increase the knowledge and competence of the attendees along with improving the scientific insight on the understanding of the molecular basis of these lethal diseases based on recent discoveries. The meeting is intended to provide a summary of advances in science and clinical management of liver cancer, including the research conducted in Mount Sinai.

1. Compare the epidemiology and disparities of liver cancer in the US.
2. Review the current role of surgical and loco-regional treatments for liver cancer.
3. Diagram the molecular rationale for immune therapies in HCC.
4. Critical review of molecular therapies and SBRT in the management of advanced HCC

This activity is complimentary:

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™ (6.00 hours), Non-Physician Attendance (6.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Friday, December 17, 2021

If you are interested in supporting this event as an exhibitor, please email [email protected] for further information.

We gratefully acknowledge our virtual exhibitors: Celsion, Eisai, Exelixis, FujiFilm, Genentech, Gilead

 

ACKNOWLEDGEMENTS:

This activity is made possible in part by educational grants from:

AstraZeneca

Bayer HealthCare 

Boston Scientific

Celsion

Eisai, Inc.

Exelixis

Glycotest, Inc.

Merck & Co.